| Rhopressa (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop in the evening |
| Chem Specs | netarsudil dimesylate 0.02% |
| Quantities | 2.5ml |
| Cost | 341.88 |
| Class | Rho kinase1 and norepinephrine transporter inhibitor. |
| Action | Increases trabecular outflow and decreases aqueous production. |
| Usage | Indicated for lowering IOP with open-angle glaucoma or ocular hypertension. |
| IOP reduction similar (or slightly less) than latanaprost. When used in combination with latanaprost the number of patients achieving 30% IOP reduction increases from 40% to 65%. |
|
| Side Effects | Mild conjunctival hyperemia occurs in 50% to 60%, but is consistently observed in only 10% and so is considered "well tolerated". Corneal epithelial macrocysts, small conjunctival hemorrhages, and cornea verticillata(20%) which resolve on discontinuation have been reported. |
| Contraindications | None |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Pregnancy | Rat embryofetal lethality shown at 126 times normal human dose but not at 40x. |
| If used concomitantly with other drops, administer each at least 5 minutes apart. BAK 0.015% |